BioSpace News Archive

Today, Happify Health (www.HappifyHealth.com), a global leader in digital therapeutics for anxiety and depression, announced plans to develop a prescription digital therapeutic (PDT) for the treatment of migraines, following positive results from a pilot study of 5,000 migraine sufferers who used a Happify digital therapeutic.

Scientific Industries, Inc., a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three months ended September 30, 2021.

Promore Pharma AB announced the composition of the Nomination Committee for the Annual General Meeting 2022, which will be held on Tuesday 17 May 2022.

Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol ® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, provided an update on ongoing OT-101/IL-2 combination trial (the “Trial”), which has now successfully completed the safety evaluation of its safety cohort, allowing for further expansion of its clinical program into phase 2 clinical trials and higher doses.

Polypeptide Therapeutic Solutions today announced the appointment of Robert Shaw as Chief Executive Officer.

Rakovina Therapeutics Inc. announced that the Company has been selected to join a three year US$975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

Hoth Therapeutics, Inc. today announced that it has signed a Sponsored Research Agreement with North Carolina State University (" NC State ") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers .

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services division has released RENAsym® version 1A, the first version of its novel quantitative systems toxicology (QST) software for predicting and investigating drug-induced kidney injury.

Genprex, Inc. today announced that its President and Chief Executive Officer, Rodney Varner, will be presenting in November